| Date | Title | Description |
| 12.06.2024 | Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement | BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients sufferi... |
| 20.05.2024 | Third Rock, J&J neuroscience spinout Rapport is first biotech to outline summer IPO plans | The new year burst of biotech IPOs may have sputtered out months ago, but Rapport Therapeutics is a reminder that companies are still willing to test the waters of the public markets.
Rapport launched from the Third Rock conveyor belt in Ma... |
| 25.08.2023 | Rapport Therapeutics Snags $150M to Develop Precision Neurology Meds | Most available treatments for neurological disease act broadly across the brain, including in unwanted regions that cause intolerable side effects. Rapport Therapeutics — a clinical-stage biotech that was founded last year — is seeking to s... |
| 23.08.2023 |
Rapport Therapeutics Finds $150M In Series B
| San Diego- and Boston-based Rapport Therapeutics has raised $150M in a Series B funding round, the company said this morning. According to the company, the funding was led by Cormorant Asset Management, and also included Fidelity Management... |
| 23.08.2023 | Rapport Therapeutics closes $150M investment to support their ongoing clinical programs | - |
| 23.08.2023 | Rapport Therapeutics Raises $150M in Series B Funding | Rapport Therapeutics, a Boston, MA- and San Diego, CA-based clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) for neuromedicines, raised $150M in Series B funding.
The round was led by Cormor... |
| 07.03.2023 |
Rapport Therapeutics Gets $100M
| San Diego- and Boston-based Rapport Therapeutics announced this morning that it has raised $100M in a Series A funding round, to go towards its precision medicines for neurological disorders. The funding was led by Third Rock Ventures, and ... |
| 07.03.2023 | Rapport Therapeutics Raises $100M in Series A Funding | Rapport Therapeutics, a Boston, MA and San Diego, CA-based clinical-stage biotechnology company dedicated to the discovery and development of precision medicines for neurological disorders, raised $100M in Series A funding.
The round was le... |
| - | Rapport Therapeutics | “Precision medicines to match the complexity of the human brain.” |
